Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chimerix (CMRX)
NASDAQ:CMRX
Holding CMRX?
Track your performance easily
CMRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.75 - $3.80
Previous CloseN/A
Volume622.27K
Average Volume (3M)8.58M
Market Cap
$329.17M
Enterprise Value-$51.08M
Total Cash (Recent Filing)$232.02M
Total Debt (Recent Filing)$441.00K
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Mar 04, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding89,936,050
10 Day Avg. Volume1,510,887
30 Day Avg. Volume8,578,495
Standard Deviation0.43
R-Squared0.00191
Alpha0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2070.23
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.16
Enterprise Value/Revenue-321.23
Enterprise Value/Gross Profit-157.64
Enterprise Value/Ebitda0.56
Forecast
1Y Price Target
$8.00Price Target Upside125.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Chimerix News
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionThe company has already begun expanding their commercial capabilities across several fronts, including market access, distribution, reimbursement, patient services, marketing and commercial access.
Financial SupportChimerix entered into an amended and restated loan and security agreement for up to $30.0M.
Regulatory ProgressChimerix announced the NDA submission with the FDA seeking accelerated approval for dordaviprone in the recurrent H3K27M diffuse glioma setting.
Bears Say
Clinical PerformanceThe median duration of response decreased to 10.4 months, indicating a shorter period of effectiveness.
Financial And Operational RisksRisks include commercial, regulatory, clinical, manufacturing, financial, liability, and intellectual challenges.
Regulatory ChallengesProvisional approval in Australia has been pushed back to focus on the U.S. NDA filing.
---
Ownership Overview
6.14% Insiders
7.26% Mutual Funds
0.94% Other Institutional Investors
80.99% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CMRX FAQ
What was Chimerix’s price range in the past 12 months?
Chimerix lowest stock price was $0.75 and its highest was $3.80 in the past 12 months.
What is Chimerix’s market cap?
Chimerix’s market cap is $329.17M.
When is Chimerix’s upcoming earnings report date?
Chimerix’s upcoming earnings report date is Mar 04, 2025 which is in 45 days.
How were Chimerix’s earnings last quarter?
Chimerix released its earnings results on Nov 07, 2024. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.236 by -$0.024.
Is Chimerix overvalued?
According to Wall Street analysts Chimerix’s price is currently Undervalued.
Does Chimerix pay dividends?
Chimerix does not currently pay dividends.
What is Chimerix’s EPS estimate?
Chimerix’s EPS estimate is -0.26.
How many shares outstanding does Chimerix have?
Chimerix has 89,936,050 shares outstanding.
What happened to Chimerix’s price movement after its last earnings report?
Chimerix reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.236. Following the earnings report the stock price went down -6.931%.
Which hedge fund is a major shareholder of Chimerix?
Currently, no hedge funds are holding shares in CMRX
---
Chimerix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (125.35% Upside)
$8.00 (125.35% Upside)
Blogger Sentiment
Bullish
CMRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
277.65%
12-Months-Change
Fundamentals
Return on Equity
-48.59%
Trailing 12-Months
Asset Growth
-29.57%
Trailing 12-Months
Company Description
Chimerix
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
---
CMRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant progress in clinical studies and a strong financial position, despite the increased research expenses and net loss. The positive developments in the pipeline and financial management outweigh the challenges.Read More>---
CMRX Stock 12 Month Forecast
Average Price Target
$8.00
▲(125.35% Upside)
Technical Analysis
Aurinia Pharmaceuticals
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Mersana Therapeutics
―
BioCryst
―
Best Analysts Covering CMRX
1 Year
1 Year Success Rate
10/24 ratings generated profit
1 Year Average Return
+28.63%
assigned a buy rating 20 days ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +28.63% per trade.
---